Research And Markets Research And Markets

Colorectal Cancer - KOL Insight Module

  • ID: 2693690
  • October 2013
  • 127 Pages
  • FirstWord Publishing
1 of 4

The global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift due to wider generic competition in cytotoxics and increasing adoption of anti-EGFR products as first line therapies. What will be the impact on market leader Roche/Genetech's Avastin and how do leading clinicians view the changes?

The main drivers of change in the CRC market

Avastin to come under pressure?

Roche/Genetech's all-conquering Avastin (bevacizumab) is expected to come under pressure in both primary and secondary settings. The principal driver of change in the primary setting is coming from more accurate diagnosis of disease sub types. Clinical studies with patients expressing the RAS wild-type phenotype suggest they may benefit more from BMS/ Merck KGaA's Erbitux (cetuximab) and Amgen's Vectibix (panitumumab). What will be the clinical and commercial impact of such a development on Avastin as the current first line therapy of choice?

Competition will intensify in the refractory setting

Bayer's Stivarga (regorafenib) is currently the last option for patients with metastatic CRC but is dogged by adverse side effects in many patients. The product is vulnerable to Taiho Pharmaceuticals' nucleoside analogue TAS-102 and Dainippon Sumitomo Pharma's stem cell READ MORE >

Note: Product cover images may vary from those shown
2 of 4

1. Executive summary

2. Colorectal Cancer Disease Overview

3. Covering Epidemiology, Aetiology, Risk factors, Symptoms, Screening, Diagnosis, Prognosis

4. Treatment Options

5. Covering Surgery, Radiotherapy, Chemotherapy and Targeted therapies

6. Current systemic therapies

7. Cytotoxic therapies overview

- Fluorouracil
- Irinotecan
- Eloxatin (oxaliplatin; Sanofi)
- Xeloda (capecitabine; Roche)

8. Targeted therapies overview

- Avastin (bevacizumab; Genentech/Roche/Chugai)
- Erbitux (cetuximab; Bristol-Myers Squibb/Merck KGaA)
- Vectibix (panitumumab; Amgen/Takeda)
- Zaltrap (ziv-aflibercept; Regeneron/Bayer Healthcare/Sanofi)
- Stivarga (regorafenib; Bayer Healthcare/Sanofi)

9. Reimbursement of key colorectal cancer brands

10. Pipeline therapies

- TAS 102 (Taiho Pharmaceutical)
- Novel irinotecan formulations
- HA – irinotecan (hyaluronic acid irinotecan complex; Alchemia)
- NKTR-102 (etirinotecan pegol; Nektar Therapeutics)
- EZN-2208 (PEGylated irinotecan conjugate; Zhejiang Hisun Pharmaceuticals)
- Ramucirumab (ImClone Systems)
- BBI 608 (cancer stem cell inhibitor; Dainippon Sumitomo Pharma)
- OncoVAX (colorectal cancer vaccine; Vaccinogen)
- Imprime PGG (PGG glucan; Biothera)
- MGN 1703 (TLR-9 agonist; Mologen)
- BRAF and MEK inhibitors
- Tafinlar (dabrafenib; GlaxoSmithKline)
- Mekinist (trametinib; GlaxoSmithKline)

11. Unmet needs in Colorectal Cancer

12. Current and future treatment algorithm

13. Future developments in Colorectal Cancer

Note: Product cover images may vary from those shown
3 of 4

Benefit from the insights of these clinical experts!

Dr Tanios Bekaii-Saab, MD, Associate Professor, College of Medicine, The Ohio State University, and Chair, Disease Specific Research Group for Gastrointestinal Oncology, OSU Comprehensive Cancer Center, Ohio, USA.

Dr Al B Benson III, MD, FACP, Professor in Medicine-Hematology/Oncology Northwestern University Feinberg School of Medicine, Chicago, USA.

Dr Thomas H Cartwright, MD, Medical Director, US Oncology Research and medical oncology and haematology specialist working in private practice at Ocala Oncology, Florida, USA..

Dr Eric Van Cutsem, MD, PhD, Professor of Internal Medicine at the University of Leuven; Head of the Digestive Oncology Department at the University Hospital Gasthuisberg; and Board Member of Leuven Cancer Institute, Leuven, Belgium.

Dr Jean-Yves Douillard, MD, PhD, Professor of Medical Oncology at the Integrated Centres of Oncology R. Gauducheau and University of Nantes Medical School, France.

Dr Marwan G Fakih, MD, Professor and Director, Department of Medical Oncology and Therapeutics Research, City of Hope, California, USA..

Dr Bert H. O'Neil, MD, Associate Professor Clinical Research, University of North Carolina Lineberger Comprehensive Cancer Care Center, North Carolina, USA.

Dr Bassel el-Rayes, MD, Associate Professor, Emory University School of Medicine and Director, GI Oncology Translational Research Program, Winship Cancer Institute, Georgia, USA.

Dr Hans-Joachim Schmoll, MD, Director, University Hospital for Internal Medicine IV, Oncology/Haematology, Martin-Luther University, Halle, Germany.

Dr Alberto Sobrero, MD, PhD, Director of Medical Oncology Unit at S. Martino Hospital, Genova, Italy.

Dr Michael Stahl, MD, PhD, Director of the Department of Medical Oncology, Haematology and Centre of Palliative Care, and Professor, Kliniken Essen-Mitte, the academic teaching hospital of the University of Duisburg-Essen,Germany.

Dr Alan P Venook, MD, Professor, Department of Medicine (Hematology/Oncology), UCSF, San Francisco, USA.

Requested Anonymous, Professor of Medicine in the Division of Medical Oncology at a large US academic medical center.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown